Neuroendocrine Tumors

Well Differentiated

1st Line

Operable

NET0030
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors

PI: Visser
Pending
1st Priority

NET0028
Phase III 177Lu-Edototide vs Targeted Molecular Therapy w/ Everolimus in SSTR+ Neuroendocrine Tumours

PI: Aparici
Pending
1st Priority

ECOG-ACRIN-A021602
Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus

PI: Shahgufa
ECOG-ACRIN
1st Priority

Inoperable

NET0024
Phase I XmAb18087 in Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

PI: Fisher
Xencor
1st Priority

HEP0057
Phase III Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

PI: Kothary
University of Pennsylvania
3rd Priority

KEY

Pending
Link
Extension Study
ImmunoTherapy
Optional Path
Trial Posting
Enrollment on Hold
Observational Study

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu